Thus, these findings provide what we believe to be new insights into the role of APP lactylation modification in the pathogenesis of AD and establish a scientific basis for the potential development of APP lactylation-specific agonists as therapeutics for treating learning and memory deficits associated with AD and aged populations. This evidence concerns the gene APP and Alzheimer disease.